Accelerating the Next Generation of ADCs

Contract Pharma exclusive interview with Aton Biotech’s Chief Business Officer, Min Park, MBA to discuss some key trends fueling the ADC market, challenges, and solutions to accelerate the Next Generation of ADCs.

The antibody-drug conjugate (ADC) market is growing fast, fueled by breakthroughs in targeted cancer treatments and a rising number of FDA-approvals for these complex therapeutics. Valued at $11.6 billion in 2023 by Nova One Advisor, the research firm expects the global ADC market to reach $28.6 billion by 2033, growing 9.4% per year. Major players like Roche, AstraZeneca, and Pfizer are leading the way, investing heavily in this cutting-edge technology.

Contract Pharma recently interviewed Aton Biotech’s Chief Business Officer, Min Park, MBA, who discussed the company’s ADC capabilities, plans for future growth, as well as broader trends driving the ADC market forward. With so much activity in this space, moving forward we’re likely to see major advancements in cancer care and beyond.

Funding challenges, the increasing complexity of ADC design, supply chain disruptions, and high production costs remain significant obstacles. Overcoming these issues requires a strategic approach that combines technical expertise, robust quality management, and adaptability to market and regulatory changes. Many CDMOs lack the comprehensive internal capabilities needed to support the complex journey of bringing a new ADC to market, which adds further challenges for innovators. For companies with limited resources or expertise, partnering with a full-service CDMO like Aton Biotech can be essential for mitigating risks, controlling costs, and ensuring a successful outcome.

CLICK HERE to read the full article.